Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides.

Abstract	The tumor-rejection antigen SART3 possesses two antigenic epitopes (SART3(109-118) and SART3(315-323)) capable of inducing HLA-A24-restricted and tumor-specific CTLs. To determine its safety and ability to generate antitumor immune responses, 12 patients with advanced colorectal cancer were administered s.c. vaccinations of these peptides. No severe adverse events were associated with the vaccinations. Significant levels of increased cellular immune responses to both HLA-A24+ colon cancer cells and the vaccinated peptide were observed in the postvaccination peripheral blood mononuclear cells in 7 of 11 and 7 of 10 patients tested, respectively, and the higher responses were observed in those patients vaccinated with the highest dose (3 mg/injection) of the peptides. These results encourage further development of SART3 peptide vaccine for colorectal cancer patients.
Authors	Y Miyagi, N Imai, T Sasatomi, A Yamada, T Mine, K Katagiri, M Nakagawa, A Muto, S Okouchi, H Isomoto, K Shirouzu, H Yamana, K Itoh
Journal	Clinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 7 Issue 12 Pg. 3950-62 (Dec 2001) ISSN: 1078-0432 [Print] United States
PMID	11751487 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	Antigens, Neoplasm Cancer Vaccines Epitopes HLA-A Antigens HLA-A24 Antigen Immunoglobulin G RNA-Binding Proteins SART3 protein, human Immunoglobulin E
Topics	Adult Aged Antigens, Neoplasm (adverse effects, immunology, therapeutic use) Cancer Vaccines (adverse effects, immunology, therapeutic use) Colorectal Neoplasms (immunology, mortality, pathology, therapy) Epitopes (immunology) Female HLA-A Antigens (immunology) HLA-A24 Antigen Humans Hypersensitivity, Immediate Immunity, Cellular Immunoglobulin E (blood) Immunoglobulin G (blood) Male Middle Aged Neoplasm Staging RNA-Binding Proteins (adverse effects, immunology, therapeutic use) Survival Rate Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!